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Summary Temozolomide (8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one) has shown pro-
mising activity in Phase I trials against some brain (glioma) and skin (melanoma, mycosis fungoides) cancers.
Temozolomide and lomustine (CCNU) showed parallel toxicity in seven human tumour cell lines and this
generally correlated (correlation coefficients 0.87 and 0.92 respectively) with the level of expression of the
DNA repair protein 06-alkylguanine-DNA alkyltransferase (ATase, EC 2.1.1.63). Pretreating cells with the
ATase inhibitor, 06-benzylguanine (BG), potentiated cytotoxicity to a similar degree with both drugs, but did
not sensitise a cell line (ZR-75-1) expressing very low levels of this protein. When BG pretreatment was
combined with repeat doses of temozolomide a dramatic potentiation (300 fold) was seen in MAWI cells,
which express high levels of ATase, but not in a cell line (U373) expressing lower levels of ATase.
["4C]-labelled temozolomide uptake was similar in sensitive and resistant lines. Human ATase-cDNA trans-
fected xeroderma pigmentosum (XP) fibroblasts were more resistant than XP control cells to temozolomide and
the related chloroethylating agent mitozolomide and although BG completely suppressed ATase activity in
these cells, resistance was still greater than in control cells.
Temozolomide (CCRG 81045, NSC 362856) has recently
completed an extended Phase I trial at Charing Cross Hos-
pital, London and Queen Elizabeth Hospital, Birmingham
(Newlands et al., 1992). It was selected for clinical testing due
to a combination of its broad spectrum activity against a
range of murine tumours including P388 and L1210
leukaemias, M5076 sarcoma and B16 melanoma and its
limited bone marrow toxicity (Stevens et al., 1987). In the
clinic temozolomide has shown activity against high grade
glioma, malignant melanoma and mycosis fungoides. Of par-
ticular interest is its activity in a pilot study of patients with
primary brain tumours, who had relapsed following radio-
therapy (O'Reilly et al., in press). The drug exhibits marked
schedule dependency and has little activity when given as a
single dose. The recommended dose is 750 - 1000 mg m-2,
given orally, split over 5 days and repeated over a 4 week
cycle (Newlands et al., 1992).
Temozolomide rapidly degrades in physiological solutions
to form the reactive methylating species, MTIC (Stevens et
al., 1984) which reacts with DNA bases forming methyl
addition products chiefly at N7-guanine, N3-adenine and 06_
guanine (Bull, 1988). O6-alkylguanine is repaired by the pro-
tein 06-alkylguanine DNA alkyltransferase (ATase) which
captures the alkyl group onto one ofits own cysteine residues
in a stoichiometric autoinactivating reaction (Tano et al.,
1990). There is increasing evidence that O6-alkylguanine is a
major cytotoxic lesion following exposure to methylating and
chloroethylating agents: for example, in ATase deficient cells,
bacterial (Margison & O'Connor, 1990) or mammalian
ATase cDNA transfection (Wu et al., 1992) confers resist-
ance to these agents. If, as would appear likely,
temozolomide has a similar mechanism of cell killing, one
possible method of potentiating its cytotoxicity would be to
deplete the ATase protein. In the present study we have
investigated the relationship between temozolomide cytotox-
icity, ATase expression and the effect of 06-benzylguanine
(BG), an inhibitor of ATase (Dolan et al., 1991).
Materials and methods
Materials
Tissue culture medium was purchased from ICN Biomedicals
Ltd (High Wycombe, UK) and foetal calf serum from Gibco
Ltd (Paisley, UK). 06-benzylguanine (BG) was kindly sup-
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plied by Dr R.C. Moschel (NCI-Frederick Cancer Research
& Development Center, Frederick, Maryland, USA).
Temozolomide and its chloroethyl analogue, mitozolomide
(8-carbamoyl-3-(2-chloroethyl) imidazo [5,1-d]-l1,2,3,5-
tetrazin-4-(3H)-one), were synthesised by May and Baker Ltd
(Dagenham, UK) and stored as solutions in DMSO at
- 70°C. All other chemicals were purchased from Sigma
Chemical Co. Ltd. (Poole, UK).
Cytotoxicity studies
Cell lines were routinely grown as monolayers in DMEM
supplemented with 10% foetal calf serum, 25 mm HEPES,
glutamine and penicillin/streptomycin. Cytotoxicity studies
were carried out in HEPES-free medium in a 5% CO2 atmo-
sphere. 750-1000 cells/well were plated in 96 well plates and
after overnight incubation were treated for 2 h with or with-
out 33 J.M BG. Temozolomide or CCNU was then added for
1 h in the same medium, the final DMSO concentration not
exceeding I%. The cells were grown for a further 7 days in
fresh medium and assayed for protein content by the NCI
sulphorhodamine assay (Skehan et al., 1990; Wasserman &
Twentyman, 1988); growth studies showed that cells were in
log phase growth during the assay period. For the repeat
temozolomide dosing schedule cells were given consecutive
24h treatments, with fresh medium each day. Assays were
carried out at least in duplicate.
Human ATase cDNA-transfected or control XP cells (Fan
et al., 1991) were grown in MEM and 1000 cells/well were
plated. After a 3 h incubation, temozolomide, freshly diluted
into MEM was added and the plates incubated for 5 days.
Survivals were assayed as previously described (Morten et al.,
1992). In the BG experiments 300 cells were plated in tripli-
cate onto 9 cm plates and allowed to attach for 5 h. BG was
added (10 tM in MEM) 3 h prior to treatment with temo-
zolomide which was freshly diluted into MEM containing
10jIM BG. After 7 days colonies were stained with Giemsa
and counted.
06-alkytguanine DNA alkyltransferase assay
This was carried out as described previously (Lee et al.,
1991). The basis of the assay is the incubation ofcell extracts
with DNA which contains 06-methylguanine labelled with
[3H] in the methyl group after which the DNA is degraded to
acid soluble material and the protein, which contains the
methylated ATase, is collected by centrifugation and
counted. The protein content of the cells was determined
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with a BioRad protein assay kit using bovine serum albumin
as a standard.
Cellular uptake of['4C]-labelled temozolomide
8-carbamoyl-3-[4C]methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-
(3H)-one (specific activity 26.3 mCi mmole 1) was kindly
supplied by Dr John Slack (Aston Molecules Ltd, Birmin-
gham, UK). Cell suspensions (5 x 106 ml-) were equilibrated
at 4°C and treated with 200jAM of the labelled drug. 106 cells
were pipetted into eppendorf tubes and centrifuged through
250iLl of an oil mixture (4:1 'Three-in-One'/Dow Corning
silicone oil). The aqueous layer was aspirated and the oil
layer gently washed with a further 300 ,.l of saline. After
centrifugation both layers were aspirated, the cell pellet dis-
solved in Protosol and added to scintillation vials containing
Optiphase.
Results
Cytotoxicity studies
The data in Table I and Figure 1 show a reasonable correla-
tion between the sensitivity (as measured by the concentra-
tion which gives 50% inhibition ofgrowth or ICW) of tumour
cell lines to temozolomide (r = 0.87) or CCNU (r = 0.92)
and their ATase content. The slopes are nearly parallel
except that CCNU is approximately five times more toxic on
a molar basis. One exception was the MCF-7 line which is
moderately sensitive to temozolomide and has a relatively
high ATase activity. Cell lines pretreated with a non-toxic
dose of BG were up to 3.5-fold more and 6-fold more
sensitive to temozolomide and CCNU respectively.
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Figure 1 Cytotoxicity (IC50) of temozolomide (0) and CCNU
(X) versus cellular ATase levels in the human tumour cell lines
(in order of increasing ATase levels): ZR-75-1, U87MG, U373,
LS174T, LOVO, MCF-7 and MAWI.
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Figure 2 Cytotoxicity of temozolomide in pZipneoSV(X)l-
transfected (0,O) or phAT-transfected (A,V) XP-derived cell
lines in the presence (0,4) or absence (0,V) of IOJiM BG.
Error bars indicate ± 1 s.d.
The control XP cells (transfected with pZipneoSV(X)l
(Fan et al., 1990), which express barely detectable levels of
ATase, are 4-5-fold more sensitive to temozolomide or the
CCNU-related agent mitozolomide than the human ATase
cDNA-transfected cells (Table I). In a colony forming assay
for the cytotoxicity of temozolomide (Figure 2), BG pretreat-
ment showed a similar degree of potentiation for the human
ATase-transfected XP cells as for the tumour cells, but had
no measurable effect on the control XP cells, which do not
express ATase. Although BG depleted the ATase activity in
the former cells (see below), they remained more resistant to
temozolomide than the control pZip transfected fibro-
blasts.
The repeat dosing schedule showed dramatic potentiation
of temozolomide toxicity by BG in MAWI and MCF-7 cells
(Figure 3, Table II): after treatment with five 24 h doses the
former cell line was over 300-fold more sensitive when BG
was present. Multiple doses of temozolomide, by itself, were
not more toxic than a single 24 h dose in either cell line. In a
similar experiment on U373 cells, which have a low level of
ATase, the presence of BG caused only a 3-fold potentiation,
after four 24 h doses.
Alkyltransferase levels
We found that the concentrations of BG used in this study
rapidly reduced to an undetectable level (data not shown),
the initially high ATase content of MAWI cells and human
ATase cDNA transfected XP fibroblasts. HPLC analysis
showed that BG was stable in tissue culture medium for at
least 24 h at 37°C.
Table I Single dose cytotoxicity
Temozolomide CCNU
IC50 IC50 IC50 IC50 ATase
Cell [-BG] [+ BG] [-BG] [+ BG] (fmolmg-'
line (IM) (fiM) Ratioa ("LM) (fLM) Ratioa protein)
Breast
ZR-75-1 32 23 1.4 12 25 0.5 <10
MCF-7 325 171 1.9 70 31 2.2 581.3
Astrocytoma
U87MG 172 131 1.3 28 8.8 3.2 21.9
U373 131 78 1.7 15 12 1.2 53.2
Colorectal
LS174T 873 632 1.4 73 13 5.7 199.6
LOVO 848 323 2.6 92 32 2.9 529.0
MAWI 1173 335 3.5 133 30 4.4 992.3
XP lines
pZip 23b _ _ (0.8)b,c - - <2
phAT 100b _ _ (4.2)bc - - 1240
Cells were exposed to ± o6-benzylguanine (BG) prior to a single dose of temozolomide or CCNU. "IC50 [-BG]/ICM [+ BG]. bResults
obtained by MTT assay (Wasserman et al., 1988). cFigures in parentheses refer to mitozolomide.
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Table II Repeated dose temozolomide cytotoxicity (IC5o)
Cell Day I Day 2 Day 3 Day 4 Day S
line -BG + BG -BG + BG -BG + BG -BG + BG -BG + BG
U373 51 18
MAWI 319 196 350 59 383 21 383 7.2 326 1.0
MCF-7 319 89 319 51 375 11
Cells were exposed to + 06-benzylguanine (BG) prior to repeated daily doses of
temozolomide.
We also investigated the temozolomide concentration
range, following a 3 h incubation, which caused a decrease in
the ATase content of U373, MCF-7, LOVO and MAWI cell
lines. There was a 50% reduction at 50-100gtM for each line
(Figure 4), despite a 3-4-fold difference in the single dose
temozolomide cytotoxicity between MCF-7 and the colorec-
tal lines (LOVO and MAWI). We found a similar reduction
in the more sensitive U373 line, although the ATase levels
were close to the detection limit of the assay.
To eliminate the possibility of differences in temozolomide
transport we studied the cell uptake of the ['4C]-labelled
compound by the most sensitive and resistant cell lines (ZR-
75-1 and MAWI respectively). Figure 5 shows that uptake
was very rapid at 4°C, being complete within 5 min in both
cell lines. Similar amounts of drug were found in both cell
lines when adjusted for protein concentration. Rapid uptake
at 4°C was consistent with passive diffusion of temozolomide
previously shown in two lymphoid lines (Bull & Tisdale,
1987).
Discussion
The dose-limiting toxicity of chloroethylating agents such as
mitozolomide and the chloroethylnitrosoureas is severe
myelosuppression, whereas temozolomide is tolerated at ap-
proximately ten times the MTD of mitozolomide (Newlands
et al., 1985; Newlands et al., 1992). It is reasonable to suggest
that this is a function of chloroethylation versus methylation
and whilst only the former reaction can lead to DNA cross-
links through initial binding to the 06-position of guanine
(Tong et al., 1982), the possibility that other chloroethyl
lesions in DNA may be more abundant or more cytotoxic
than the methyl equivalents must also be considered (Lud-
lum, 1990). The observation that ATase can prevent the
formation of crosslinks by repairing the precursor 06-chloro-
ethylguanine and that ATase expression can provide protec-
tion against cell killing by chloroethylnitrosoureas (Jelinek et
al., 1988; Margison et al., 1990; Margison & O'Connor,
1990; Wu et al., 1992) have given rise to attempts to poten-
tiate the cytotoxic effects of chloroethylnitrosoureas using
BG in xenografts and this has had some success (Dolan et
al., 1990a; 1990b; 1991). The question of whether normal
tissues would be equally affected is only beginning to be
addressed (Fairbairn and Margison, submitted).
In the present report, we have shown a parallel toxicity for
temozolomide and CCNU (after 1 h drug exposure) with a
number of human tumour cell lines, correlating with their
ATase content. This suggests that methylation at the o6-
position of guanine in DNA is an important cytotoxic lesion
for temozolomide. Pretreating cells with BG causes a modest
(<4-fold) increase in temozolomide toxicity, presumably
because temozolomide itself causes partial depletion of the
ATase protein through DNA methylation. The degree of
enhancement for temozolomide and CCNU are of a similar
order ofmagnitude. In a colony assay, human ATase cDNA-
transfected fibroblasts pretreated with BG remained more
resistant to temozolomide than control transfected fibro-
blasts, although the ATase protein was eliminated. This is
unlikely to be due to differences in temozolomide transport
and may simply reflect resynthesis of ATase by the phAT
fibroblasts to diminish the effect of pretreatment with the
inhibitor.
We found a major potentiation by BG of temozolomide
toxicity (300-fold) in the MAWI cell line after 5 days treat-
ment. A similar degree of enhancement was seen in MCF-7
cells which also contain high levels of ATase, but only a
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Figure 3 Cytotoxicity ratio of repeated daily doses of
temozolomide in MAWI ((X), MCF-7 (V) or U373 (#) human
tumour cell lines of drug only, ICo (-BG), compared to prein-
cubation with BG, IC5o (+BG).
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Figure 4 Effect of increasing concentrations of temozolomide on
ATase levels in the human tumour cell lines: LOVO (0), MAWI
(X), MCF-7 (V), U373 ()
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Figure 5 Uptake of radiolabel at 4°C by cells treated with
'4C-temozolomide. MAWI (0), ZR-75-1 (X).1302 J.C. BAER et al.
small effect in U373 cells which have low levels. This implies
that the continued presence of the ATase inhibitor permits a
build up of DNA damage. It is interesting that a flow
cytometry study (Catapano et al., 1987) has shown that
temozolomide induces a block in S (late)-G2-M both in vitro
and in mice. This block occurs at least two cell divisions after
drug treatment, in contrast to many DNA-interacting agents,
including mitozolomide (Broggini et al., 1986), which induce
a pre-mitotic block a few hours after drug treatment.
Pharmacokinetic studies (Newlands et al., 1992) have
shown that patients receiving temozolomide on a repeated
dose schedule attain a maximum plasma concentration of
about 50gM, which is similar to the ICo values of our cell
lines with low levels of ATase. Distribution studies in mice
show that temozolomide like mitozolomide (Brindley et al.,
1986, unpublished results) has good tissue distribution in-
cluding penetration into the tumour tissue and across the
blood-brain barrier. It is also known that the brain contains
low levels of ATase in comparison with other tissues in the
body such as liver and spleen (Citron et al., 1991; Pegg &
Byers, 1992). Further increases in activity might be obtained
by ATase depletion but potentiation of cytotoxicity may also
occur in normal cells (Fairbairn & Margison, submitted). It
may be that BG or a derivative which is selectively
accumulated by tumours, could extend the range of tem-
ozolomide-sensitive tumours.
This work was supported by the Cancer Research Campaign.
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